Sofinnova Partners

cb Email

Status

ACTIVE

Global HQ

Paris, France

Countries of investment

Estonia
Latvia
Lithuania
Czech Republic
Slovakia
Albania
Belgium
Bosnia and Herzegovina
Bulgaria
Croatia
Cyprus
Denmark
Finland
Germany
Greece
Hungary
Iceland
Ireland
Italy
Luxembourg
North Macedonia
Netherlands
Poland
Portugal
Romania
Serbia
Slovenia
Spain
Sweden
Switzerland
Ukraine
United Kingdom
France
San Marino
United States

Investment stages

Seed
Series A
Series B

Industries

Biotechnology
Diagnostics
Life Sciences
Health Tech
Medical Devices
Pharma
Precision Medicine
Science

About
Sofinnova Partners backs life-science companies developing novel therapeutics, medical technologies, and breakthrough biological platforms with the potential for global clinical impact. The firm collaborates deeply with researchers, clinical institutions, and pharma partners to guide companies through preclinical validation, clinical trials, and regulatory pathways. Its strategy combines scientific rigor, high-conviction portfolio construction, and the ability to scale capital from incubation to multi-stage clinical investment.

Min check size: $100K
Max check size: $30M
Fund size: Unlock
NPS: Unlock

Investment Thesis

Sofinnova invests across the full life-sciences spectrum—biotech, medtech, and therapeutic innovation—supporting scientific founders from company creation to late clinical development. The firm seeks highly differentiated science backed by world-class researchers, targeting breakthroughs that address critical unmet medical needs across Europe and North America.

Lead investor: Unlock
Co Invest: Unlock
Number of exits: Unlock
Preferred contact method: Unlock

Manager's Experience

The management team comprises seasoned MDs, PhDs, and life-sciences veterans with extensive experience in drug discovery, clinical development, regulatory pathways, and global venture capital. Many have held senior roles at leading pharmaceutical companies and biotech firms across Europe and the United States, bringing decades of scientific and investment expertise to support breakthrough therapeutic innovation.

Sofinnova Partners Contacts Information

Primary contact

Unlock

Secondary contact

Unlock

Team

Antoine Papiernik – Chairman & Managing Partner; Henrijette Richter – Managing Partner; Graziano Seghezzi – Managing Partner; Alexandra Abreu – Analyst

Crossover Strategy; Joe Anderson – Partner

Crossover Strategy; Guillaume Baxter – Partner

Industrial Biotech; Anna Belousova – Associate

Industrial Biotech; Maina Bhaman – Partner

Capital Strategy; Joško Bobanović – Partner

Industrial Biotech; Gabriella Camboni – Partner

Biovelocita; Claire Catherinet – Senior Associate

Crossover; Mariam Cherifi – Associate

Industrial Biotech; Matthieu Coutet – Partner

Biovelocita; Cécile Dupont – Partner

MD Start; Marie Duranteau – Associate / Program Manager

Biovelocita; Lucia Faccio – Partner

Telethon Strategy; Marion Gasperment – Principal / Program Manager

MD Start; Aseem Ghaghda – Senior Associate

Capital Strategy; Anta Gkelou – Partner

Capital Strategy; Kinam Hong – Partner

Crossover Strategy; Mano Iyer – Partner

MD Start; Ankeet Jethwa – Senior Associate

Capital Strategy; Edward Kliphuis – Partner

Digital Medicine; Michael Krel – Partner

Industrial Biotech; Alex Leech – Partner

Biovelocita; Mary McCarthy – Partner

Industrial Biotech; Cedric Moreau – Partner

Crossover Strategy; Karl Naegler – Partner

Capital Strategy; Javier Nunez-Vicandi – Principal

Digital Medicine; Anne Osdoit – Partner

MD Start; Aishwarya Parthasarathy – Associate

Digital Medicine; Cristina Pelizon – Senior Associate / Program Manager

Biovelocita; Paola Pozzi – Partner

Telethon; Elliott Puttock – Analyst

Crossover; Tiziana Rossetti – Principal

Telethon; Gabriela Sachet Fernandez – Analyst

Industrial Biotech; Daniel Sieiro – Associate

Capital Strategy; Jacques Theurillat – Partner

Crossover; Simon Turner – Partner

Digital Medicine; Antonin Weckel – Analyst

Capital Strategy; Zhizhong Joel Yao – Partner

Biovelocita; Anis Belmili – Fund Accountant; Thomas Bermudes – Senior Legal Counsel; Christophe Blanche – Chief Financial Officer; Armance Bordes – General Counsel / Head of Legal & Compliance; Anne-Sophie Castaigne – Head of Operations & Projects; Gabriel Challot – Communications Designer; Sylvie Chapoy – Executive Assistant; Eugénie Cotte – Analyst; Sandy Diep – Accountant; Matthieu Dreno – Senior Fund Accountant; Bertrand Echalard – Management Company Accounting; Martina Epi – Office Assistant; Hortense Fouilland – Legal Counsel; Ahmed Fourati – Investor Relations & Reporting Officer; Juliette Grant – Executive Assistant; Johanna Guacide – Funds Accounting Manager; Stéphanie Huiban – Head of Information Systems; Paul Kilpatrick – Executive Assistant; Marc Lahoudie – IT Systems & Application Support; Sandrine Le Penru – Executive Assistant; Aziliz Le Roux – Investor Relations Manager; Bommy Lee – Head of Communications; Nathalie Loreaux – Investor Relations & Reporting Manager; Julia Metzger – Executive Assistant; Agnès Pauquet – Head of HR; Héloïse Percheron – Senior HR Officer; Enzo Petrelluzzi – Project Manager; Paola Pizzi – Head of Operations Italy; Pamela Putz – Events & Community Manager; Estelle Rigaux – Senior Compliance Officer; Pauline Roca – Office & Travel Manager; Sara Saoud – Investor Relations Analyst; Monique Saulnier – Senior Advisor; Karine Smolovic – Compliance Officer; Perrine Soupault – Senior Legal Counsel; Nicolas Tuvi – Analyst; Ligia Vela-Reid – Communication Manager; Lamia Verney – Executive Assistant; Gérard Hascoët – Venture Partner

MD Start; Josh Makower – Venture Partner; Silvano Spinelli – Venture Partner; Martin T. Rothman – Venture Partner; Andrew M. Weiss – Venture Partner